Mesoblast Keynote Presentations to Feature at 2019 Annual Meeting of the International Society for Cell and Gene Therapy
May 23 2019 - 6:00AM
Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular
medicines for inflammatory diseases, will feature at the
International Society for Cell and Gene Therapy (ISCT) annual
meeting being held May 29-June 1, 2019.
In the plenary session ‘Commercial Strategies for Expanding
Global Cell and Gene Therapy Access’, Mesoblast Chief Executive Dr
Silviu Itescu will discuss the Company’s product pipeline and
commercialization plans for its lead cell therapy remestemcel-L.
The presentation will focus on potential approval and market launch
of remestemcel-L in the United States for the treatment of
pediatric steroid-refractory acute graft versus host disease
(aGVHD), and subsequent proposed label extension for adults with
aGVHD and additional indications in children and adults.
Additionally, Mesoblast’s Global Head of Research and
Development, Dr Paul Simmons, will discuss the Company’s commercial
scale manufacturing capabilities, its proprietary technologies, and
strategies for meeting expected peak market demand.
About ISCTEstablished in 1992, the
International Society for Cell and Gene Therapy (ISCT) is a growing
global society of clinicians, regulators, researchers,
technologists and industry partners. ISCT is the global leader
focused on pre-clinical and translational aspects of developing
cell-based therapeutics, thereby advancing scientific research into
innovative treatments for patients. ISCT offers a unique
collaborative environment that addresses three key areas of
translation: Academia, Regulatory and Commercialization. Through
strong relationships with global regulatory agencies, academic
institutions and industry partners, ISCT leads the advancement of
research into standard of care. Headquartered in Canada, ISCT is
comprised of over 1400 international cell and gene therapy experts
across five geographic regions and representation from over 60
countries, ISCT members are part of a global community of peers,
thought leaders and organizations invested in cell therapy
translation. ISCT is incorporated as a not for profit
organization, 501(c)(3) in Washington DC.
About Mesoblast Mesoblast
Limited (ASX:MSB; Nasdaq:MESO) has leveraged its proprietary
technology platform to establish a broad portfolio of late-stage
allogeneic (off-the-shelf) product candidates with three product
candidates in Phase 3 trials – acute graft versus host disease,
chronic heart failure and chronic low back pain due to degenerative
disc disease. Through a proprietary process, Mesoblast selects rare
mesenchymal lineage precursor and stem cells from the bone marrow
of healthy adults and creates master cell banks, which can be
industrially expanded to produce thousands of doses from each donor
that meet stringent release criteria, have lot to lot consistency,
and can be used off-the-shelf without the need for tissue matching.
Mesoblast has facilities in Melbourne, New York, Singapore and
Texas and is listed on the Australian Securities Exchange (MSB) and
on the Nasdaq (MESO). www.mesoblast.com
Forward-Looking Statements This announcement
includes forward-looking statements that relate to future events or
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. We make such forward-looking statements pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Forward-looking
statements should not be read as a guarantee of future performance
or results, and actual results may differ from the results
anticipated in these forward-looking statements, and the
differences may be material and adverse. Forward-looking statements
include, but are not limited to, statements about the timing,
progress and results of Mesoblast’s preclinical and clinical
studies; Mesoblast’s ability to advance product candidates into,
enroll and successfully complete, clinical studies; the timing or
likelihood of regulatory filings and approvals; and the pricing and
reimbursement of Mesoblast’s product candidates, if approved. You
should read this press release together with our risk factors, in
our most recently filed reports with the SEC or on our website.
Uncertainties and risks that may cause Mesoblast’s actual results,
performance or achievements to be materially different from those
which may be expressed or implied by such statements, and
accordingly, you should not place undue reliance on these
forward-looking statements. We do not undertake any obligations to
publicly update or revise any forward-looking statements, whether
as a result of new information, future developments or
otherwise.
For further information, please contact:
Julie MeldrumCorporate CommunicationsT: +61 3
9639 6036E: julie.meldrum@mesoblast.com
Schond GreenwayInvestor RelationsT: +1 212 880
2060E: schond.greenway@mesoblast.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024